Table 1.
Ongoing clinical trials for the treatment of bone metastases in neuroendocrine neoplasms.
| ID | STATUS 1 | PHASE | STUDY TITLE | INTERVENTION | PRIMARY OUTCOME |
|---|---|---|---|---|---|
| NCT03986593 | Recruiting | Not Applicable | Cryoablation of Bone Metastases from Endocrine Tumors | Cryoablation | Change in the local disease status of the cryoablation-treated bone metastases; absence of neurological impairment and/or pain. |
| NCT02743741 | Recruiting | Not Applicable | Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor PositiveNeuroendocrine Tumors | Lutetium-177 Octreotate | The proportion of patients who are progression-free using RECIST 1.1 criteria [Time frame: up to 12 months]. |
| NCT02489604 | Recruiting | 2 | Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors | 177Lu-DOTATATE 25.9 GBq activity; 177Lu-DOTATATE 18.5 GBq activity | Disease control rate (DCR) [Time frame: up to 7 years]. |
| NCT03478358 | Recruiting | 1 | Treatment Using 177Lu-DOTA-EB-TATE in Patients with Advanced Neuroendocrine Tumors | 177Lu-DOTA-EB-TATE 1; 177Lu-DOTA-TATE; 177Lu-DOTA-EB-TATE 2; 177Lu-DOTA-EB-TATE 3. | Change of standardized uptake value of 68Ga-DOTA-TATE before and after treatment in metastatic neuroendocrine tumors [Time frame: 1 year]. |
| NCT00004074 | Completed | 1 | Interleukin-12 and Trastuzumab in Treating Patients with Cancer That Has High Levels of HER2/Neu | Recombinant interleukin-12; ABI007/carboplatin/trastuzumab | Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs), graded using the CTCAE v2.0 criteria. |
| NCT00005842 | Completed | 1 | Trastuzumab Plus R115777 in Treating Patients with Advanced or Metastatic Cancer | Trastuzumab; tipifarnib | Determine the maximum tolerated dose of R115777 when administered with trastuzumab (Herceptin). |
1 Last update from clinicaltrials.gov was on 26 August 2019.